Madrigal Pharmaceuticals (MDGL) Scheduled to Post Earnings on Tuesday

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($6.06) per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share for the quarter, missing the consensus estimate of ($5.26) by ($0.42). During the same period in the previous year, the firm posted ($4.98) earnings per share. On average, analysts expect Madrigal Pharmaceuticals to post $-22 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL stock traded up $2.95 during trading hours on Tuesday, hitting $204.02. The company's stock had a trading volume of 435,464 shares, compared to its average volume of 526,308. The stock has a market cap of $4.06 billion, a PE ratio of -10.23 and a beta of -0.47. Madrigal Pharmaceuticals has a 12-month low of $119.76 and a 12-month high of $322.67. The company has a 50 day moving average of $242.13 and a 200 day moving average of $214.05. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 0.28.

Analysts Set New Price Targets

A number of research firms recently weighed in on MDGL. JMP Securities boosted their price target on shares of Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the stock an "outperform" rating in a research report on Friday, March 15th. TD Cowen upped their target price on shares of Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the stock an "outperform" rating in a research note on Friday, March 15th. Evercore ISI boosted their price target on shares of Madrigal Pharmaceuticals from $325.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 20th. Oppenheimer lifted their target price on Madrigal Pharmaceuticals from $320.00 to $375.00 and gave the company an "outperform" rating in a report on Friday, March 15th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $336.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Thursday, March 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $356.73.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, Director James M. Daly sold 32,489 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $102.77, for a total value of $3,338,894.53. Following the sale, the director now directly owns 1,198 shares in the company, valued at approximately $123,118.46. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director James M. Daly sold 32,489 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $102.77, for a total transaction of $3,338,894.53. Following the completion of the sale, the director now owns 1,198 shares in the company, valued at approximately $123,118.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard S. Levy sold 11,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $257.48, for a total value of $2,832,280.00. Following the completion of the sale, the director now owns 10,298 shares of the company's stock, valued at approximately $2,651,529.04. The disclosure for this sale can be found here. Insiders sold a total of 146,496 shares of company stock worth $31,362,420 over the last ninety days. Company insiders own 23.92% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.